Sino Biopharm and MediTrust Health Partner to Advance Drug-Insurance Integration Model in China
核心洞察
Sino Biopharmaceutical Limited and Shanghai MediTrust Health Technology Group signed a strategic cooperation agreement at CIIE 2025 to explore innovative drug-insurance integration models.
The partnership aims to help patients access high-quality, affordable medicines earlier through commercial insurance channels, reducing pressure on public medical insurance funds.
MediTrust Health has serviced approximately 393 million commercial health insurance policies and achieved cumulative savings of RMB 6.7 billion in out-of-pocket costs for patients.
Sino Biopharmaceutical Limited and Shanghai MediTrust Health Technology Group Co., Ltd. (搜索) signed a strategic cooperation agreement during the 8th China International Import Expo (CIIE) on November 10, 2025, to jointly explore a new model of drug-insurance integration that aims to help patients access high-quality, affordable medicines at an earlier stage.
The signing ceremony was attended by Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, and Mr. Wang Rundong, President of MediTrust Health, with Mr. Li Zhigang, Chairman of MediTrust Health, serving as witness.
Strategic Partnership Framework
Mr. Tse Hsin emphasized the significance of commercial health insurance as a critical channel for innovative drugs to reach the market, particularly as demographics evolve and healthcare reforms deepen. "This not only eases pressure on public medical insurance funds but also fuels R&D investment, fostering a sustainable industry cycle," he stated.
The partnership positions MediTrust Health as a pivotal platform connecting pharmaceutical companies, insurers, and patients, giving it a unique advantage in advancing drug-insurance integration. The two companies plan to explore AI, data collaboration, and innovative payment solutions to establish new benchmarks for industry coordination.
Patient-Centric Approach
Mr. Wang Rundong outlined MediTrust Health's patient-centric vision, leveraging AI and data-driven multi-payment infrastructure to streamline the diagnosis-treatment-payment journey. "We envision insurance as more than a reimbursement tool—it should be a bridge to better healthcare, ensuring patients facing critical illnesses (搜索) gain earlier, more affordable access to treatment with greater peace of mind," he explained.
The partnership aligns with China's "Healthy China 2030" strategy, aiming to enhance drug accessibility and build a win-win ecosystem for both pharmaceutical and insurance sectors.
Company Profiles and Market Impact
Sino Biopharm operates as a leading Chinese innovative pharmaceutical group with annual revenue of approximately RMB 30 billion, ranking 38th among the Top 50 Global Pharmaceutical Companies. The company maintains a robust pipeline of over 120 innovative drugs and focuses on oncology (搜索), hepatology (搜索), respiratory (搜索), and surgery therapeutic areas.
MediTrust Health has established significant market presence, having serviced approximately 393 million commercial health insurance policies as of December 31, 2024. The company's City Supplementary Insurance projects cover 160 cities and have achieved cumulative savings of RMB 6.7 billion in out-of-pocket costs for patients.
Technology Integration
The collaboration will integrate MediTrust Health's AI-empowered technologies with Sino Biopharm's innovative drug portfolio. MediTrust Health's platform includes Smart Pharma Solution, which provides pharmaceutical companies with comprehensive commercialization solutions across the product lifecycle, and Smart Insurance Solution, offering end-to-end support to health insurers through proprietary AI-empowered technologies.
The partnership also incorporates Care2Pay, an all-in-one user platform that allows users to discover payment solutions and complete direct billing transactions, ultimately delivering more comprehensive, quality, and accessible healthcare to patients and their families.